ADMA BIOLOGICS, INC. is an end-to-end commercial biopharmaceutical company focused on manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Co.'s products include: BIVIGAM, an Intravenous Immune Globulin (IVIG) product indicated for the treatment of Primary Humoral Immunodeficiency (PI); ASCENIV, an IVIG product indicated for the treatment of PI; and Nabi-HB, which is indicated for the treatment of acute exposure to blood containing HBsAg and other listed exposures to Hepatitis B. The ADMA stock yearly return is shown above.
The yearly return on the ADMA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ADMA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|